Martín Espinosa-Bravo

Martín Espinosa-Bravo

Auto-generated profile, based on publicly available information

Martín Espinosa-Bravo

Breast Surgical Oncology, Breast Cancer Center, Hospital Universitario Vall d'Hebron, Barcelona, Spain

Research Focus & Metrics

Academic Career Length

16Years (2011-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 December 2017 in Annals of Surgical Oncology
Verified
Journal Article
Closed access
PDF file
CSChristian Siso
Christian Siso
JTJuan de Torres
Juan de Torres
AEAntonio Esgueva-Colmenarejo
Antonio Esgueva-Colmenarejo
MEMartin Espinosa-Bravo
Martin Espinosa-Bravo
NRNeus Rus
Neus Rus
IRIsabel Teresa Rubio
Isabel Teresa Rubio

1 January 2015 in European Journal of Surgical Oncology
Verified
Journal Article
Closed access
IRIsabel Teresa Rubio
Isabel Teresa Rubio
SDS. Diaz-Botero
S. Diaz-Botero
AEA. Esgueva
A. Esgueva
RRR. Rodriguez
R. Rodriguez
TCT. Cortadellas
T. Cortadellas
MEM. Espinosa-Bravo
M. Espinosa-Bravo

16 February 2022 in Cancer Research
Verified
Journal Article
Open access
PDF file
BPBenedetta Pellegrino
Benedetta Pellegrino
AHAndrea Herencia-Ropero
Andrea Herencia-Ropero
ALAlba Llop-Guevara
Alba Llop-Guevara
FPFlaminia Pedretti
Flaminia Pedretti
AMAlejandro Moles-Fernández
Alejandro Moles-Fernández
VSVioleta Serra
Violeta Serra
PARP inhibitors (PARPi) are approved drugs for platinum-sensitive, high-grade serous ovarian cancer (HGSOC) and for breast, prostate, and pancreatic cancers (PaC) harboring genetic alterations impairing homologous recombination repair (HRR). Detection of nuclear RAD51 foci in tumor cells is a marker of HRR functionality, and we previously established a test to detect RAD51 nuclear foci. Here, we aimed to validate the RAD51 score cut off and compare the performance of this test to other HRR deficiency (HRD) detection methods. Laboratory models from BRCA1/BRCA2-associated breast cancer, HGSOC, and PaC were developed and evaluated for their response to PARPi and cisplatin. HRD in these models and patient samples was evaluated by DNA sequencing of HRR genes, genomic HRD tests, and RAD51 foci detection. We established patient-derived xenograft models from breast cancer (n = 103), HGSOC (n = 4), and PaC (n = 2) that recapitulated patient HRD status and treatment response. The RAD51 test showed higher accuracy than HRR gene mutations and genomic HRD analysis for predicting PARPi response (95%, 67%, and 71%, respectively). RAD51 detection captured dynamic changes in HRR status upon acquisition of PARPi resistance. The accuracy of the RAD51 test was similar to HRR gene mutations for predicting platinum response. The predefined RAD51 score cut off was validated, and the high predictive value of the RAD51 test in preclinical models was confirmed. These results collectively support pursuing clinical assessment of the RAD51 test in patient samples from randomized trials testing PARPi or platinum-based therapies. Significance: This work demonstrates the high accuracy of a histopathology-based test based on the detection of RAD51 nuclear foci in predicting response to PARPi and cisplatin.

11 April 2013 in Breast Cancer Research and Treatment
Verified
Journal Article
Closed access
PDF file
VPVicente Peg
Vicente Peg
MEMartín Espinosa-Bravo
Martín Espinosa-Bravo
BVBegoña Vieites
Begoña Vieites
FVFelip Vilardell
Felip Vilardell
JAJosé R. Antúnez
José R. Antúnez
IRIsabel T. Rubio
Isabel T. Rubio


29 October 2015 in Annals of Surgical Oncology
Verified
Journal Article
Closed access
PDF file
IRIsabel Teresa Rubio
Isabel Teresa Rubio
AEAntonio Esgueva-Colmenarejo
Antonio Esgueva-Colmenarejo
MEMartin Espinosa-Bravo
Martin Espinosa-Bravo
JSJuan Pablo Salazar
Juan Pablo Salazar
IMIgnacio Miranda
Ignacio Miranda
VPVicente Peg
Vicente Peg